Investor Relations

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir; CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus.



  • Aug 22, 2017
  • 4:00 PM ET
  • $4.41
  • 0.00 (0.00%)
  • N/A
Delayed at least 20 minutes.
Refresh quote

SEC Filings

Date Filing Description View
Apr 16, 2013 4 wollaeger, timothy HTML PDF XLS Add to Briefcase
Apr 16, 2013 8-K current report HTML PDF XLS Add to Briefcase
Apr 11, 2013 S-8 registration statement HTML PDF XLS Add to Briefcase
Apr 11, 2013 424B4 prospectus filed pursuant to rule 424 HTML PDF XLS Add to Briefcase
Apr 11, 2013 FWP free writing prospectus - filing under securities act rules 163/433 HTML PDF XLS Add to Briefcase
Page: FirstPrevious ...
... NextLast
= add file to Briefcase



The Chimerix ticker is CMRX and it is traded on the Nasdaq Global Market.

2505 Meridian Parkway
Suite 100
Durham, NC 27713

You can view our Board of Directors by visiting the Board of Directors section of our Investor Relations website.

You can view our management team by visiting the Management section of our Investor Relations website.

December 31

Chimerix does not expect to declare or pay any cash or other dividends on our common stock.

Chimerix does not currently have a direct stock purchase plan.

Quarterly and annual reports, as well as other SEC filings, can be accessed on the Financial Information portion of our Investor Relations website or directly from the SEC at

The transfer agent and registrar for our common stock is:

Computershare Trust Company, N.A.


The transfer agent and registrar’s address is:

P.O. Box 43078

Providence, Rhode Island 02940

Please submit your question using the form below.

* Indicates required field